• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Researchers identify chemical compound that inhibits Ebola virus replication

Bioengineer by Bioengineer
March 28, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Georgia State University

ATLANTA–An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University.

The researchers found benzoquinoline inhibited the ability of Ebola virus to multiply and reproduce in cell culture. The findings are published in the journal Antiviral Research.

Ebola virus, a member of the filovirus family, is an enveloped, single-stranded RNA virus that causes severe disease in humans. The largest outbreak on record for the filovirus family was caused by Ebola virus in West Africa between 2013 and 2016, resulting in more than 28,000 infections and more than 11,000 deaths.

Only experimental treatments were available, and survivors, including health care workers, are at risk for persistent infections from the virus remaining in sites that can tolerate foreign substances without eliciting an inflammatory immune response, such as the eye and testes. There are no approved drugs to treat Ebola virus or other filovirus infections, so there is a critical need for new therapeutic approaches. A potential antiviral target is the viral machinery and activities involved in carrying out RNA synthesis for Ebola virus.

"This work provides a foundation for the development of novel antiviral agents to combat Ebola virus," said Dr. Christopher Basler, director of the Center for Microbial Pathogenesis and professor in the Institute for Biomedical Sciences at Georgia State and a Georgia Research Alliance Eminent Scholar in Microbial Pathogenesis.

In this study, the researchers screened a library of 200,000 small molecule compounds to identify potential inhibitors of Ebola virus RNA synthesis. They identified 56 hits that inhibited Ebola virus activity by more than 70 percent, while showing less than a 20 percent chance of being toxic to cells. They discovered three chemical structures with potent antiviral activity against Ebola virus in cell culture.

Human lung epithelial cells and human embryonic kidney cells were exposed to several viruses, Ebola virus, Marburg virus, vesicular stomatitis virus and Zika virus, and the antiviral effects of the three chemical structures were observed.

One of these chemical structures, benzoquinoline, showed antiviral activity against Ebola virus and was also active against another deadly filovirus, Marburg virus. Benzoquinoline was also effective against vesicular stomatitis virus from the rhabdovirus family, which can infect insects, cattle, horses and pigs, and Zika virus, which is spread to humans by mosquitoes.

"This study is part of a larger effort to find new therapies to treat highly dangerous Ebola virus infections," said lead author Dr. Priya Luthra of Georgia State.

###

Co-authors of the study include Sudip Khadka, Megan R. Edwards and Sampriti De of Georgia State; Jue Liang, Shuguang Wei, Bruce Posner and Joseph M. Ready of the University of Texas Southwestern Medical Center; and Colette A. Pietzsch and Alexander Bukreyev of the University of Texas Medical Branch at Galveston.

The study is funded by the National Institutes of Health.

To read the study, visit https://www.sciencedirect.com/science/article/pii/S016635421730640X.

Media Contact

LaTina Emerson
[email protected]
404-413-1353
@GSU_News

http://www.gsu.edu

Original Source

http://news.gsu.edu/2018/03/28/researchers-identify-chemical-compound-that-inhibits-ebola-virus-replication/?utm_source=press_release&utm_medium=email&utm_campaign=ebola

Share12Tweet7Share2ShareShareShare1

Related Posts

Children’s SARS-CoV-2 Antibodies Show Stronger FcR Binding

Children’s SARS-CoV-2 Antibodies Show Stronger FcR Binding

August 23, 2025
Link Between Type 2 Diabetes and Heart Failure

Link Between Type 2 Diabetes and Heart Failure

August 23, 2025

Exploring Type 3 APS, T1DM, and LADA Insights

August 23, 2025

Thermal Vests Alleviate Mealtime Anxiety in Anorexia Patients

August 23, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Capturing a Split-Second Glimpse of Cellular Activity in Freeze-Frame

Children’s SARS-CoV-2 Antibodies Show Stronger FcR Binding

Link Between Type 2 Diabetes and Heart Failure

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.